Oncology Central

EGFR–tyrosine kinase mutation testing methods in non-small-cell lung cancer: new diagnostic guidance is NICE


Over 39,000 people in the UK are newly diagnosed with lung cancer each year and non-small-cell lung cancer (NSCLC) comprises 72% of cases [101,102]. A high proportion of NSCLC diagnoses are made at a late stage, locally advanced or metastatic, which limits treatment options. New drugs targeted towards tumor genotypes (stratified medicine) are improving the management of a range of cancers including advanced NSCLC. Between 10 and 15% of adenocarcinomas tested in UK NSCLC patients have oncogenic activation of the EGF receptor (EGFR) caused by somatic mutation of the tyrosine kinase (TK) domain of EGFR. NSCLC patients with EGFR–TK mutations have a high probability of response to small molecule inhibitors that target the mutant EGFR TK domain.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.